ASA Monitor December 2024, Vol. 88, 28–29.
Shockwave Medical expands U.S. Peripheral IVL portfolio with enhanced catheter
Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the full U.S. launch of the Shockwave E8 Peripheral IVL Catheter, following clearance by the FDA. The Shockwave E8 catheter is designed to optimize the treatment of patients with calcified femoro-popliteal and below-the-knee peripheral artery disease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI).
With 400 pulses delivered twice per second, and eight emitters across an 80mm balloon, Shockwave E8 can treat longer lesions more efficiently. With an increased catheter working length of 150cm, physicians can extend their IVL treatment to reach below-the-knee and very distal lesions. Combined with Shockwave L6, Shockwave M5+, and Shockwave S4 IVL catheters, the addition of Shockwave E8 offers physicians a complete IVL portfolio to treat challenging calcified lesions across the entire peripheral anatomy.
Source: asamonitor.pub/4eVvwsH
Leave a Reply
You must be logged in to post a comment.